Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells

Novel pharmacological strategies capable of inhibiting pro-oncogenic MDM2 beyond its p53-dependent functions represent increasingly attractive therapeutic strategies to treat solid and hematological cancers that are dependent upon MDM2/MDMX, regardless of TP53 mutational status. Utilizing a novel fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Sean F. Cooke, Thomas A. Wright, Gillian Lappin, Elka Kyurkchieva, Yuan Yan Sin, Jiayue Ling, Alina Zorn, Bria O’Gorman, William Banyard, Chih-Jung Chang, Helen Wheadon, Danny T. Huang, George S. Baillie, Connor M. Blair
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
MDM2
MDMX
dimerization
disruptor peptide
TP53 mutant cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329925000980
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950329925000980

Similar Items